Dr. Park is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
5841 S Maryland Ave
# MC2030
Chicago, IL 60637Phone+1 773-702-1061
Education & Training
NIH Clinical CenterPost-Doctoral Fellowship, 2002 - 2007
Memorial Sloan Kettering Cancer CenterFellowship, 2000 - 2002
University of ChicagoChief Residency, Neurology, 1999 - 2000- University of ChicagoResidency, Neurology, 1997 - 2000
- University of Chicago (NorthShore)Internship, Transitional Year, 1996 - 1997
Loma Linda University School of MedicineClass of 1996- Loma Linda UniversityFellowship, 1993 - 1994
Certifications & Licensure
IL State Medical License 2018 - 2026
NJ State Medical License 2023 - 2025
PA State Medical License 2007 - 2010
NY State Medical License 2000 - 2008- American Board of Psychiatry and Neurology Neurology
- United Council for Neurologic SubspecialtiesNeuro-Oncology
Awards, Honors, & Recognition
- Merit and Career Development Awards American Society of Clinical Oncology
Clinical Trials
- Study of Imatinib, a Platelet-derived Growth Factor Receptor Inhibitor, and LBH589, a Histone Deacetylase Inhibitor, in the Treatment of Newly Diagnosed and Recurrent Chordoma Start of enrollment: 2011 Oct 01
- QUILT-3.011 Phase 2 Yeast-Brachyury Vaccine Chordoma Start of enrollment: 2015 May 01
- Biomarker Analysis of Central Nervous System Tumors Start of enrollment: 2016 Feb 25
- Join now to see all
Publications & Presentations
PubMed
- NAD+ Metabolic Enzyme Inhibitor as Radiosensitizer for Malignant Meningioma and its Modulation of P53 Expression.Yifan Lv, Yuxuan Deng, Jie Feng, Jinqiu Liu, Mingxu Yang
Molecular Cancer Therapeutics. 2024-11-04 - TGF-β and BMP signaling are associated with the transformation of glioblastoma to gliosarcoma and then osteosarcoma.Aiguo Li, John C Hancock, Martha Quezado, Susie Ahn, Nicole Briceno
Neuro-Oncology Advances. 2023-12-19 - 5 citationsA Nicotinamide Phosphoribosyltransferase Inhibitor, FK866, Suppresses the Growth of Anaplastic Meningiomas and Inhibits Immune Checkpoint Expression by Regulating STAT1.Yuxuan Deng, Boyi Hu, Yazhou Miao, Jing Wang, Shaodong Zhang
Frontiers in Oncology. 2022-01-01
Journal Articles
- Clinical Decision Making in the Era of Immunotherapy for High Grade-Glioma: Report of Four CasesMartha Quezado, Brett J Theeler, Deric M Park, Edjah Nduom, Nancy Garren, Surabhi Ranjan, Kareem A Zaghloul, BioMed Central
Professional Memberships
- Fellow
Other Languages
- Korean
Industry Relationships
- Scientific Advisor, Innate Repair2018 - Present
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
